Invasive Aspergillosis of the Spleen in the setting of Ibrutinib use

Burger JA Chiorazzi N . B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol 2013; 34: 592–601.

Burger JA . Nurture versus nature: the microenvironment in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2011; 2011: 96–103.

Pan Z Scheerens H Li SJ , et al. Discovery of selective irreversible inhibitors for bruton's tyrosine kinase. ChemMedChem 2007; 2: 58–61.

Singh J Petter RC Kluge AF . Targeted covalent drugs of the kinase family. Curr Opin Chem Biol 2010; 14: 475–480.

Byrd JC Brown JR O'Brien S , et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014; 371: 213–223.

Burger JA Tedeschi A Barr PM , et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 2015; 373: 2425–2437.

Samhouri Y, Shah R and Khan C. Chronic Lymphocytic Leukemia: Rapidly changing treatment landscape, advances in Hematologic Malignancies, Gamal Abdul Hamid, IntechOpen, DOI: 10.5772/intechopen.88070. Available from: https://www.intechopen.com/chapters/69188.

Paydas S . Management of adverse effects/toxicity of ibrutinib. Crit Rev Oncol Hematol 2019; 136: 56–63.

Barbosa CC DeAngelis LM Grommes C . Ibrutinib associated infections: a retrospective study. J Clin Oncol 2017; 35: e19020–e19020.

Burger JA Barr PM Robak T , et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia 2020; 34: 787–798.

Rogers K . Ibrutinib and fungus: an invasive concern. Blood 2018; 131: 1882–1884.

CHMP. Imbruvica, INN-ibrutinib, https://www.ema.europa.eu/en/documents/product-information/imbruvica-epar-product-information_en.pdf (2021).

Lionakis MS Dunleavy K Roschewski M , et al. Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer Cell 2017; 31: 833–843.

Wang ML Blum KA Martin P , et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood 2015; 126: 739–745.

Jain P Keating M Wierda W , et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood 2015; 125: 2062–2067.

Varughese T Taur Y Cohen N , et al. Serious infections in patients receiving ibrutinib for treatment of lymphoid cancer. Clin Infect Dis 2018; 67: 687–692.

Faisal MS Shaikh H Khattab A , et al. Cerebral aspergillosis in a patient on ibrutinib therapy-A predisposition not to overlook. J Oncol Pharm Pract 2019; 25: 1486–1490.

Okamoto K Proia LA Demarais PL . Disseminated cryptococcal disease in a patient with chronic lymphocytic leukemia on ibrutinib. Case Rep Infect Dis 2016; 2016: 4642831.

Baron M Zini JM Challan Belval T , et al. Fungal infections in patients treated with ibrutinib: two unusual cases of invasive aspergillosis and cryptococcal meningoencephalitis. Leuk Lymphoma 2017; 58: 2981–2982.

Fiedler K Sindrilaru A Terszowski G , et al. Neutrophil development and function critically depend on bruton tyrosine kinase in a mouse model of X-linked agammaglobulinemia. Blood 2011; 117: 1329–1339.

Arthurs B Wunderle K Hsu M , et al. Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia. Respir Med Case Rep 2017; 21: 27–29.

Adverse Drug Reaction Probability Scale (Naranjo) in Drug Induced Liver Injury. Livertox: clinical and research information on drug-induced liver injury. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, 2012.

Patterson TF Thompson GR Denning DW , et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of america. Clin Infect Dis 2016; 63: e1–e60.

Caron F Leong DP Hillis C , et al. Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis. Blood Adv 2017; 1: 772–778.